Skip to main content
. 2017 Oct 24;161(2):412–420. doi: 10.1093/toxsci/kfx219

Figure 2.

Figure 2.

Representative H + E stained liver sections, all at 10× with 40× inset, with scale in (A). (A) Control untreated C57BL/6 mice; (B) Troglitazone, C57BL/6 mice treated with troglitazone only; (C) Pioglitazone, C57BL/6 mice treated with pioglitazone only; (D) PD1/Troglitazone/anti-CTLA-4, PD1−/− mice treated with troglitazone and anti-CTLA-4; (E) PD1/Pioglitazone/anti-CTLA-4, PD1−/− mice treated with pioglitazone and anti-CTLA-4; (F) Tolcapone, C57BL/6 mice treated with tolcapone only; (G) Entacapone, C57BL/6 mice treated with entacapone only; (H) PD1/Tolcapone/anti-CTLA-4 = PD1−/− mice treated with tolcapone and anti-CTLA-4; and (I) PD1/Entacapone/anti-CTLA-4, PD1−/− mice treated with entacapone and anti-CTLA-4.